A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence (AI) platform, to treat a patient with advanced cancer, completely halting disease ...
Sep 4, 2018
0
6
Immune activation and inflammation persist in the majority of treated HIV-infected individuals and is associated with excess risk of mortality and morbidity. A new study by Boston University School of Medicine (BUSM) researchers ...
Aug 27, 2018
0
10
Bacteria—especially Gram-negative strains—are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed. Faced with these challenges, investigators are studying ...
Aug 10, 2018
0
3
New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy. Researchers at the Weizmann Institute of Science, in collaboration ...
Jul 25, 2018
0
4
In 2016, funded by a $16 million grant from Scythian, the multidisciplinary Miller School team embarked on a five-year study to examine the effects of combining CBD (a cannabinoid derivative of hemp) with an NMDA antagonist ...
Jul 16, 2018
0
30
(HealthDay)—Compared to treatment with an inhaled glucocorticoid alone, combination therapy with a long-acting β2-agonist (LABA) and an inhaled glucocorticoid is not associated with a significantly higher risk of serious ...
Jun 28, 2018
0
0
While the human immunodeficiency virus (HIV) has largely dropped from news headlines since the 1990s, at the end of 2016 there were 36.7 million people living with the infection, and of those only 53 per cent had access to ...
May 3, 2018
1
18
Antimicrobial resistance caused by "superbugs" is a major public health issue of global concern. Drug-resistant infections kill around 700,000 people worldwide each year. The figure could increase up to 10 million by 2050, ...
Apr 23, 2018
0
6
A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when give in combination, may enhance the immune system's ability to kill melanoma tumors deficient in the tumor suppressor ...
Apr 17, 2018
0
1
The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to ...
Apr 16, 2018
0
6
